Why the study?
Masters athletes have a higher prevalence of certain cardiovascular abnormalities than less active peers, yet available management guidelines are generally derived from symptomatic sedentary patients, limiting their applicability to highly trained individuals.
This joint EAPC/ESC and ACC Clinical Consensus Statement provides a structured, expert-based framework and shared decision-making approach for diagnosing and managing abnormal cardiovascular findings in Masters athletes aged ≥35 years.
Answers are grounded in this paper and cite their sources.
Supports individualized evaluation of masters athletes; extends consensus guidance with quantified risks for AF, calcification, dilatation, and fibrosis.
Exercise training improves cardiovascular health and reduces the risk for future cardiovascular events and mortality. However, emerging evidence suggests that Masters athletes may have a higher prevalence of cardiovascular abnormalities, such as atrial arrhythmias, coronary atherosclerosis, aortic dilatation, and myocardial fibrosis, compared to their less active peers. The clinical management of Masters athletes may be challenging as available guidelines for such conditions are generally based on data derived from symptomatic sedentary patients, limiting their applicability to highly trained individuals. Other unique challenges in the clinical assessment of Masters athletes include differences in symptomatic presentations compared to sedentary individuals, potential resistance to the initiation of pharmacologic treatment, and the increasing availability of consumer wearable health data that may provide relevant information on their cardiovascular health status. The purpose of this joint EAPC/ESC and ACC Clinical Consensus Statement is to provide an in-depth update on the current state of knowledge on abnormal cardiovascular findings in Masters athletes. We present an expert-based approach on the diagnostic assessment, management, and prognosis of (i) atrial fibrillation, (ii) bradyarrhythmias, (iii) ventricular arrhythmias, (iv) coronary atherosclerosis, (v) aortic dilatation, (vi) myocardial fibrosis, and (vii) exercise-induced arrhythmogenic cardiomyopathy. Clinical challenges, areas of ongoing controversy, and uncertainty and the potential underlying mechanisms are discussed. We also present future perspectives and research directives to further refine current best practice strategies. This includes the need for clinical outcome studies, dedicated randomized controlled trials in athletes, and international registries with diverse populations and longitudinal follow-up to evaluate the natural history of cardiac abnormalities and facilitate development of evidence-based approaches in the clinical management of Masters athletes with cardiovascular abnormalities.
No takes yet. Share an insight, caveat, or question.
Eijsvogels et al. (2026) studied Abnormal cardiovascular findings in Masters athletes (atrial fibrillation, bradyarrhythmias, ventricular arrhythmias, coronary atherosclerosis, aortic dilatation, myocardial fibrosis, exercise-induced arrhythmogenic cardiomyopathy). Long-term habitual and competitive exercise training / Expert consensus management strategies vs. Sedentary or less active peers from the general population was evaluated. Masters athletes have an increased prevalence of atrial fibrillation, coronary calcification, aortic dilatation, and myocardial fibrosis requiring individualized shared decision-making.
Synapse has enriched 10 related papers. Consider them for comparative context: